Teva Pharmaceutical and Regeneron Pharmaceuticals have reported positive top-line data from a phase III clinical trial of fasinumab to treat chronic pain in patients with osteoarthritis (OA) of the knee or hip.

Results from the trial showed that the drug met all primary and key secondary endpoints at week 16 primary efficacy analysis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It was observed that subjects administered with the drug candidate experienced significantly less pain and improved functional ability, compared to the placebo group.

Formulated by Regeneron using its VelocImmune technology, fasinumab is an investigational candidate that targets the nerve growth factor (NGF) protein associated with pain signalling regulation.

Fasinumab is being co-developed by Regeneron and Teva under a global collaboration agreement.

The randomised, double-blind, placebo-controlled phase III trial evaluated the safety and tolerability of subcutaneous 1mg dose of fasinumab every four or eight weeks over 52 weeks of active treatment.

The co-primary endpoints are change in pain and physical function from baseline at week 16. Fasinumab therapy continued for additional 36 weeks, followed by a 20-week follow-up study. The long-term primary safety analysis is set to be carried out at 72 weeks.

“We look forward to advancing our pivotal phase III fasinumab programme in patients with osteoarthritis of the knee or hip.”

Upon analysis of interim data, the drug candidate was found to be generally well tolerated. The adverse events (AEs) were similar to those observed in prior fasinumab trials.

Regeneron Pharmaceuticals president and chief scientific officer George Yancopoulos said: “We are encouraged by this data and look forward to advancing our pivotal phase III fasinumab programme in patients with osteoarthritis of the knee or hip who currently have very limited therapeutic choices to treat their chronic pain, other than with non-steriodal anti-inflammatory drugs or opioids.”

Currently, fasinumab is being assessed in a total of three phase III trials for treating chronic pain caused by OA of the knee or hip.

One of the trials is designed to investigate the drug candidate’s long-term safety, while the remaining two studies compare it to standard pain therapies.